Literature DB >> 19071182

Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response.

Bethany Hansen1, Mary Belfast, George Soung, Liping Song, Patricia M Egan, Robert Capen, Harm Hogenesch, Ralph Mancinelli, Stanley L Hem.   

Abstract

Hepatitis B surface antigen (HBsAg) is known to adsorb to aluminum hydroxide adjuvant (AH) by ligand exchange between its accessible phosphate groups and surface hydroxyl groups of the adjuvant. To study the effect of the binding strength, five vaccines were prepared with AH or four samples of AH that were modified by pretreatment with different concentrations of potassium dihydrogen phosphate. The adsorptive coefficients ranged from 3660 to 250mL/mg based on the Langmuir adsorption isotherm and degrees of elution ranged from 1 to 31% when the vaccines were exposed to interstitial fluid in vitro. When tested in mice the four vaccines containing phosphate-treated AH (PTAH) induced significantly greater antibody responses than the vaccine containing AH, which had the highest adsorptive coefficient and the smallest degree of elution of HBsAg. The results indicated that antibody production is reduced when the antigen is adsorbed too strongly. Thus, the strength of adsorption of the antigen to an aluminum-containing adjuvant can affect the immunogenicity of the vaccine and should be optimized during vaccine formulation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19071182     DOI: 10.1016/j.vaccine.2008.11.078

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  29 in total

Review 1.  Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns.

Authors:  Martin F Bachmann; Gary T Jennings
Journal:  Nat Rev Immunol       Date:  2010-10-15       Impact factor: 53.106

Review 2.  A rational, systematic approach for the development of vaccine formulations.

Authors:  Garry L Morefield
Journal:  AAPS J       Date:  2011-02-23       Impact factor: 4.009

3.  Phosphate substitution in an AlOOH - TLR4 adjuvant system (SPA08) modulates the immunogenicity of Serovar E MOMP from Chlamydia trachomatis.

Authors:  Lucian Visan; Violette Sanchez; Margaux Kania; Aymeric de Montfort; Luis M de la Maza; Salvador Fernando Ausar
Journal:  Hum Vaccin Immunother       Date:  2016-04-22       Impact factor: 3.452

Review 4.  Conjugate Vaccine Immunotherapy for Substance Use Disorder.

Authors:  Paul T Bremer; Kim D Janda
Journal:  Pharmacol Rev       Date:  2017-07       Impact factor: 25.468

Review 5.  Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts.

Authors:  Calvin C Willhite; Nataliya A Karyakina; Robert A Yokel; Nagarajkumar Yenugadhati; Thomas M Wisniewski; Ian M F Arnold; Franco Momoli; Daniel Krewski
Journal:  Crit Rev Toxicol       Date:  2014-10       Impact factor: 5.635

6.  The role of adjuvant in mediating antigen structure and stability.

Authors:  Latoya Jones Braun; Aimee M Eldridge; Jessica Cummiskey; Kelly K Arthur; Deborah S Wuttke
Journal:  J Pharm Sci       Date:  2011-12-28       Impact factor: 3.534

7.  Alum as an adjuvant for nanoparticle based vaccines: A case study with a hybrid nanoparticle-based nicotine vaccine.

Authors:  Yun Hu; Daniel Smith; Zongmin Zhao; Theresa Harmon; Paul R Pentel; Marion Ehrich; Chenming Zhang
Journal:  Nanomedicine       Date:  2019-06-10       Impact factor: 5.307

8.  Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge.

Authors:  Yuhong Xiao; Yuhong Zeng; Edward Alexander; Shyam Mehta; Sangeeta B Joshi; George W Buchman; David B Volkin; C Russell Middaugh; Stuart N Isaacs
Journal:  Vaccine       Date:  2012-11-12       Impact factor: 3.641

Review 9.  Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability.

Authors:  Tanya Clapp; Paul Siebert; Dexiang Chen; LaToya Jones Braun
Journal:  J Pharm Sci       Date:  2010-08-25       Impact factor: 3.534

10.  Increasing the potency of an alhydrogel-formulated anthrax vaccine by minimizing antigen-adjuvant interactions.

Authors:  Allan Watkinson; Andrei Soliakov; Ashok Ganesan; Karie Hirst; Chris Lebutt; Kelly Fleetwood; Peter C Fusco; Thomas R Fuerst; Jeremy H Lakey
Journal:  Clin Vaccine Immunol       Date:  2013-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.